Company Overview
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and changed its name to Opus Genetics, Inc. in November 2020. The company was founded in 2018 and is headquartered in Durham, North Carolina.
Recent Developments
- Dec 2025 Revenue of $14.20M (+29.1% YoY); net profit $-49.59M.
- Trailing 12 Months Year-on-year growth — revenue -73.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -73.80% |
Stock Price Performance
| 1 Year: | +294.55% |
| 6 Months: | -9.01% |
| 3 Months: | +7.69% |
| 1 Month: | +18.58% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)58.80 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IRD Opus Genetics, Inc. PHARMA | 4.34 | -3.36 | $361.07M | 0.00% | -90.90% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | - | 100.00K | 489.00K | 0 | 0 | 0 | 1.75M | 3.67M | 11.94M | 1.71M | 1.11M | 3.87M | 4.37M | 2.88M | 3.08M | 2.16M | 755.00K |
| Operating Income | -3.85M | -4.42M | -4.82M | -4.66M | -4.37M | -4.86M | -3.91M | -3.72M | -3.92M | -3.95M | -4.28M | -4.22M | -4.90M | -5.89M | -5.00M | -4.68M | -4.97M | -3.94M | -2.99M | -2.28M | -2.73M | -1.26M | -1.95M | -5.19M | -7.14M | -4.23M | -6.51M | -4.94M | -4.54M | -6.13M | -5.39M | 6.39M | -7.71M | -8.33M | -8.01M | -9.93M | -8.91M | -8.31M | -14.36M | -16.48M |
| Net Income | -2.21M | -4.27M | -3.23M | -4.03M | -2.85M | -4.15M | -1.77M | -2.87M | -525.48K | -21.61M | 947.06K | -1.04M | -3.59M | -2.07M | -3.84M | -5.34M | -3.12M | -2.34M | -2.46M | -1.96M | -3.09M | -1.60M | -1.25M | -39.01M | -7.14M | -4.23M | -6.59M | -4.93M | -4.53M | -5.79M | -4.96M | 5.56M | -7.11M | -7.76M | -7.53M | -8.19M | -7.42M | -17.45M | -65.53M | -8.10M |
| Diluted EPS | - | - | - | - | - | - | -0.08 | - | - | -0.91 | 0.03 | -0.04 | -0.12 | - | -0.12 | - | - | - | - | - | -0.87 | -0.43 | -0.33 | -3.57 | -0.52 | -0.25 | -0.35 | -0.25 | -0.22 | -0.28 | -0.24 | 0.25 | -0.29 | -0.30 | -0.29 | -0.24 | -0.12 | -0.25 | -0.75 | -0.14 |
| R&D Expense | - | 2.89M | 3.24M | 3.10M | - | 3.47M | 2.24M | 2.30M | - | 2.26M | 2.54M | 2.64M | - | 4.06M | 3.43M | 2.89M | - | 2.24M | 1.65M | 1.13M | 456.79K | 231.61K | 149.59K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | 3.00M | 0 | 589.00K | 39.85M | 19.05M | 10.99M | 14.20M |
| Operating Income | - | - | - | - | - | - | - | -6.47M | -10.31M | -16.13M | -6.58M | -7.98M | -13.27M | -18.26M | -16.41M | -17.35M | -20.54M | -4.19M | -19.97M | -22.70M | 18.23M | -10.56M | -62.07M | -38.60M |
| Net Income | -1.18M | -2.78M | -3.27M | -6.35M | -6.49M | -4.44M | -3.68M | -2.90M | -14.02M | -11.34M | -6.23M | -9.50M | -18.52M | -14.38M | -9.31M | -25.29M | -14.37M | -6.17M | -24.62M | -56.69M | 17.89M | -9.99M | -57.53M | -49.59M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.28 | -3.82 | 0.87 | -0.46 | -2.15 | -0.80 |
| R&D Expense | - | - | - | - | - | - | - | 3.18M | 3.93M | 11.99M | 3.39M | 3.25M | 7.02M | 12.15M | 10.09M | 10.72M | 13.11M | 5.48M | - | - | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2001 | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | - | - | - | - | 16.22M | 13.69M | 14.92M | 19.56M | 33.53M | 24.81M | 21.04M | 28.29M | 16.04M | 1.78M | 17.68M | 26.08M | 48.99M | 53.95M | 36.86M | 50.24M |
| Total Equity | 3.89M | 2.71M | 2.48M | -564.17K | 4.83M | 3.21M | 958.19K | -2.60M | 4.90M | 10.40M | 10.71M | 9.53M | 12.63M | 26.58M | 18.78M | 17.06M | 16.77M | -1.70M | -7.56M | -13.47M | 22.22M | 46.24M | 49.91M | 6.72M | 15.35M |
| Cash & Equivalents | - | - | - | - | - | - | - | 369.13K | 7.30M | 12.34M | 9.86M | 13.49M | 18.69M | 9.83M | 10.20M | 11.58M | 8.90M | 8.74M | 12.20M | - | 24.53M | 42.63M | 50.50M | 30.32M | 45.09M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 1.13M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | 5.82M | 2.98M | 5.39M | 6.93M | 6.95M | 6.03M | 3.99M | 11.52M | 5.48M | 9.34M | 31.15M | 3.85M | 2.75M | 4.04M | 11.29M | 34.90M |
| Current Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.15M | 9.34M | 3.19M | 3.85M | 2.75M | 4.04M | 11.29M | 7.78M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | -15.42M | -18.84M | -3.59M | -6.80M | -19.37M | 14.31M | -1.11M | -25.58M | -35.25M |
| Investing Cash Flow | 1.34M | -660.04K | -545.92K | 2.19M | 845.52K | -9.37M | 11.91M | -25.00K | 539.00K | -100.00K | 0 | 0 | 1.21M | 0 |
| Financing Cash Flow | 10.73M | 12.69M | 13.60M | 8.05M | 12.34M | 22.11M | 6.77M | 4.70M | 21.12M | 27.61M | 3.79M | 8.98M | 4.19M | 50.02M |
| Capital Expenditure | - | - | - | - | - | - | - | -25.00K | -0 | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | -3.62M | -6.80M | - | - | - | - | - |
| Share Buybacks | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -139.8% | - | -3,854.8% | 45.7% | -55.5% | -564.7% | -271.9% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -205.6% | - | -9,625.3% | 44.9% | -52.4% | -523.4% | -349.3% |
| ROE % | -43.5% | -112.0% | 580.2% | -131.5% | -201.8% | -463.6% | 141.5% | -59.2% | -134.9% | -106.0% | -65.3% | -75.2% | -69.7% | -76.6% | -54.6% | -150.8% | 845.7% | 81.6% | 182.8% | -255.1% | 38.7% | -20.0% | -855.6% | -323.1% |
| ROCE % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -159.3% | 55.5% | -137.7% | -102.2% | 39.4% | -21.2% | -242.8% | -90.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Caligan Partners, LP | 7.35% | 6.08M | $31.48M |
| 2 | Adage Capital Partners GP L.L.C. | 7.30% | 6.03M | $31.23M |
| 3 | Bios Capital Management, LP | 4.46% | 3.68M | $19.08M |
| 4 | Blackrock Inc. | 3.77% | 3.12M | $16.14M |
| 5 | Balyasny Asset Management LP | 3.74% | 3.09M | $16.00M |
| 6 | Nantahala Capital Management, LLC | 3.70% | 3.06M | $15.86M |
| 7 | Vanguard Capital Management LLC | 3.58% | 2.96M | $15.33M |
| 8 | Boxer Capital Management, LLC | 3.41% | 2.81M | $14.58M |
| 9 | Trails Edge Capital Partners, LP | 3.32% | 2.74M | $14.21M |
| 10 | Millennium Management Llc | 2.79% | 2.30M | $11.92M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IRD
Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences
Topline data from Phase 1/2 Cohort 1 of OPGx-BEST1 gene therapy program to be presented during investor conference call and webcast on September 9 at 8:00 a.m. ET Full clinical dataset and additional analyses evaluating key measures of visu…
Opus Genetics shares rise 5.9% ahead of OPGx-BEST1 trial data
Opus Genetics Inc (NASDAQ:IRD) shares rose 5. 9% in pre-market trading ahead of the scheduled release of three-month topline data from Cohort 1 of its OPGx-BEST1 Phase 1/2 clinical trial.
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retin…
Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
OPGx-BEST1 Cohort 1 Topline Data Expected in Second Week of September 2026 Enrollment Completed in LCA5 Registrational Trial with Dosing Planned for Q4 2026 RDH12, MERTK and RHO Programs Advancing with Upcoming Initiation of Clinical Testin…
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
Cohort 1 Topline Data Expected in the Second Week of September 2026RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a clinical-stage biopharmaceuti…
Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes
RESEARCH TRIANGLE PARK, N.C., June 26, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindne…
IRD — Frequently Asked Questions
What is the current share price of Opus Genetics, Inc. (IRD)?
As of 2026-09-19 21:16 PDT, Opus Genetics, Inc. (IRD) trades at $4.34 on NasdaqCM. Its 52-week range is $1.10 to $5.75.
What is the market capitalisation of IRD?
Opus Genetics, Inc. (IRD) has a market capitalisation of $361.07M on NasdaqCM.
What is the P/E ratio of IRD?
IRD trades at a trailing price-to-earnings (P/E) ratio of -3.36. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -32.99.
Is IRD a good stock to buy?
This page provides a data-driven analysis of Opus Genetics, Inc. (IRD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.